McKesson Corporation (MCK) is scheduled to report second-quarter fiscal 2025 results on Nov. 6, after market close.The company delivered an earnings surprise of 10.06% in the last reported quarter. Its earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 4.82%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.MCK’s top line has been gaining primarily on the back of the rapid adoption of GLP-1 weight loss drugs as well as con ...

In its upcoming report, McKesson (MCK) is predicted by Wall Street analysts to post quarterly earnings of $6.89 per share, reflecting an increase of 10.6% compared to the same period last year. Revenues are forecasted to be $89.48 billion, representing a year-over-year increase of 15.9%. The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates dur ...

McKesson (MCK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers are better than ...

McKesson (MCK) closed the most recent trading day at $508.95, moving +0.3% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.27%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq appreciated by 0.26%.The the stock of prescription drug distributor has risen by 3.92% in the past month, leading the Medical sector's loss of 4.14% and the S&P 500's gain of 2%.Investors will be eagerly watching for the performance of McKesson in its upcomi ...

The latest trading session saw McKesson (MCK) ending at $513.67, denoting a +0.86% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.The prescription drug distributor's stock has dropped by 2.03% in the past month, exceeding the Medical sector's loss of 3.35% and lagging the S&P 500's gain of 4.31%.Investors will be eagerly watching for the performance of McKesson in its upcoming ear ...

Group 1 - The article discusses a value investing approach that emphasizes classical value ratios such as low P/B, P/FCF, and Owner Earnings discounting [1] - It highlights the importance of tracking earnings growth versus price appreciation as a key element in evaluating quality investments [1] - The author advocates for self-indexing using the Dow Jones Industrial Average combined with Joel Greenblatt's Magic Formula for tax efficiency [1] Group 2 - The author has a background in private credit and CRE mezzanine financing, indicating experience in financial markets [1] - The author is fluent in Mandarin and has worked extensively in China and Asia, suggesting a strong understanding of international markets [1]

McKesson (MCK) closed at $488.78 in the latest trading session, marking a -1.95% move from the prior day. This change lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. The prescription drug distributor's shares have seen a decrease of 13.15% over the last month, not keeping up with the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21%. The investment community will be paying close attention to the earnings perf ...

Company Performance - McKesson's stock closed at $479.06, reflecting a slight decrease of -0.02% from the previous day, underperforming compared to the S&P 500's gain of 0.4% [1] - Over the past month, McKesson shares have declined by 13.93%, which is significantly worse than the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71% [1] - The upcoming earnings report is scheduled for November 6, 2024, with projected earnings per share (EPS) of $7.09, indicating a 13.8% increase year-over-year, and expected revenue of $89.57 billion, up 16% from the same quarter last year [1] Annual Forecast - The Zacks Consensus Estimates for the entire year predict earnings of $32.07 per share and revenue of $353.23 billion, representing increases of +16.87% and +14.33% respectively compared to the previous year [2] Analyst Estimates and Valuation - Recent changes in analyst estimates for McKesson reflect evolving short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [2] - McKesson currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having decreased by 0.1% in the past month [3] - The company is trading at a Forward P/E ratio of 14.94, which is lower than the industry average of 18.16, and has a PEG ratio of 1.12 compared to the industry average of 1.92 [3] Industry Context - The Medical - Dental Supplies industry, which includes McKesson, has a Zacks Industry Rank of 175, placing it in the bottom 31% of over 250 industries [4] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this prescription drug distributor have returned -13.9%, compared to the Zacks S&P 500 composite's +1.7% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has lost 2.8%. The key question now is: What could be the stock's future direction?While m ...

The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often experience a rally. After a rapid move lower, shares of McKesson Corporation MCKhave become oversold. They have also reached a price level that may provide support. This is why our team of trading experts has made it our Stock of the Day. The red line on the chart below is called a Bollinger Band. It is two standard deviations below the 20-day moving average. According to statistics and ...